[go: up one dir, main page]

PA8658401A1 - 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen - Google Patents

18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen

Info

Publication number
PA8658401A1
PA8658401A1 PA20058658401A PA8658401A PA8658401A1 PA 8658401 A1 PA8658401 A1 PA 8658401A1 PA 20058658401 A PA20058658401 A PA 20058658401A PA 8658401 A PA8658401 A PA 8658401A PA 8658401 A1 PA8658401 A1 PA 8658401A1
Authority
PA
Panama
Prior art keywords
group
hydrogen
atom
linear
alpha
Prior art date
Application number
PA20058658401A
Other languages
English (en)
Inventor
Rolf Bohlmann
Dieter Bittler
Hermann Kuenzer
Peter Esperling
Hans-Peter Muhn
Karl-Heinrich Fritzemeier
Ulrike Fuhrmann
Katja Prelle
Steffen Borden
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36087369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PA8658401(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PA8658401A1 publication Critical patent/PA8658401A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J21/00Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34Gestagens
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • C07J53/0043 membered carbocyclic rings
    • C07J53/0083 membered carbocyclic rings in position 15/16

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE LAS NUEVAS 18-METIL-19-NOR-17-PREGN-4-EN-21,17-CARBOLACTOMAS DE LA FORMULA GENERAL I EN DONDE Z ES UN ATOMO DE OXIGENO, DOS ATOMOS DE HIDROGENO, UN GRUPO =NOR O = O =NNHSO2R, EN DONDE R ES UN ATOMO DE HIDROGENO O UN GRUPO ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 4 O BIEN 3 A 4 ATOMOS DE CARBONO, R4 ES UN ATOMO DE HIDROGENO, UN ATOMO DE HALOGENO, UN GRUPO METILO O TRIFLUOROMETILO, R6 Y/O R7 PUEDEN ESTAR EN POSICION ALPHA O BETA Y SON, DE MODO INDEPENDIENTE ENTRE SI, UN GRUPO ALQUILO DE CADENA LINEAL O RAMIFICADA CON 1 A 4 O BIEN 3 A 4 ATOMOS DE CARBONO O R6 ES UN ATOMO DE HIDROGENO Y R7 ES UN GRUPO ALQUILO DE CADENA LINEAL O RAMIFICADA EN POSICION ALPHA O BETA CON 1 A4 O BIEN 3 A 4 ATOMOS DE CARBONO O R6 Y R7 SON CADA UNO UN ATOMO DE HIDROGENO O R6 Y R7 FORMAN JUNTOS UN GRUPO METILENO EN POSICION ALPHA O BETA O UN ENLACE ADICIONAL. LOS NUEVOS COMPUESTOS DISPONEN DE UNA ACCION GESTAGENICA Y ANTIMINERALOCORTICOIDE Y SON APROPIADOS PARA PRODUCIR PREPARADOS FARMACEUTICOS, P.EJ. PARA LA ANTICONCEPCION ORAL Y EL TRATAMIENTO DE TRASTORNOS, P.E. PARA LA ANTICONCEPCION ORAL Y EL TRATAMIENTO DE TRASTORNOS PRE-, PERI- Y POSMENOPAUSICOS.
PA20058658401A 2004-12-30 2005-12-29 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen PA8658401A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004063864A DE102004063864A1 (de) 2004-12-30 2004-12-30 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
PA8658401A1 true PA8658401A1 (es) 2006-08-03

Family

ID=36087369

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20058658401A PA8658401A1 (es) 2004-12-30 2005-12-29 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen

Country Status (33)

Country Link
US (1) US20090029953A1 (es)
EP (1) EP1831240B8 (es)
JP (1) JP5043681B2 (es)
KR (1) KR20070093443A (es)
CN (1) CN101128476B (es)
AR (1) AR052657A1 (es)
AU (1) AU2005324055A1 (es)
BR (1) BRPI0518533A2 (es)
CA (1) CA2594171C (es)
CR (1) CR9223A (es)
CY (1) CY1109498T1 (es)
DE (2) DE102004063864A1 (es)
DK (1) DK1831240T3 (es)
EA (1) EA014325B1 (es)
ES (1) ES2331322T3 (es)
GT (1) GT200500394A (es)
HK (1) HK1112627A1 (es)
IL (1) IL184288A (es)
MX (1) MX2007008074A (es)
MY (1) MY145904A (es)
NO (1) NO20073257L (es)
NZ (1) NZ556150A (es)
PA (1) PA8658401A1 (es)
PE (2) PE20100736A1 (es)
PL (1) PL1831240T3 (es)
PT (1) PT1831240E (es)
RS (1) RS51128B (es)
SI (1) SI1831240T1 (es)
TW (1) TW200635942A (es)
UA (1) UA90496C2 (es)
UY (1) UY29320A1 (es)
WO (1) WO2006072467A1 (es)
ZA (1) ZA200706254B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006030416A1 (de) * 2006-06-29 2008-01-03 Bayer Schering Pharma Ag 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate
DE102007027635A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027636A1 (de) * 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007027637A1 (de) 2007-06-12 2008-12-18 Bayer Schering Pharma Aktiengesellschaft 17ß-Cyano-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063498A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063499A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft Steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063495A1 (de) * 2007-12-29 2009-09-17 Bayer Schering Pharma Aktiengesellschaft 19-Nor-Steroidderivate mit einer 15α,16α-Methylengruppe und einem gesättigten 17,17-Spirolactonring, deren Verwendung sowie diese Derivate enthaltende Arzneimittel
DE102007063500A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-(1'-Propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063501A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15, 16-Methylen-17-hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063496A1 (de) 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
DE102007063503A1 (de) * 2007-12-29 2009-07-02 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-19-nor-21-carbonsäure-Steroid y-Lacton-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel
EP2265629B1 (en) * 2008-03-05 2015-06-24 Evestra, Inc. Bismethylene-17 carbolactones and related uses
DE102008026793A1 (de) 2008-06-02 2009-12-03 Bayer Schering Pharma Aktiengesellschaft C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate
CN101623287B (zh) * 2008-07-07 2012-02-08 天津金耀集团有限公司 一种屈螺酮类似物的治疗更年期综合症的药物组合物
US8222237B2 (en) * 2008-11-25 2012-07-17 Evestra, Inc. Progestational 3-(6,6-ethylene-17B-hydroxy-3-oxo-17A-pregna-4-ene-17A-yl)propionic acid G-lactones
WO2010066354A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2010066349A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft Verwendung von 17beta-cyano-19-androst-4-en-derivaten zur herstellung eines arzneimittels in depot-form zur parenteralen anwendung sowie depot-arzneimittel enthaltend 17beta-cyano-19-androst-4-en-derivate zur parenteralen anwendung
WO2010066355A1 (de) * 2008-12-12 2010-06-17 Bayer Schering Pharma Aktiengesellschaft VERWENDUNG VON 17β- CYANO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG
WO2012059594A1 (en) 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959322A (en) * 1960-09-22 1976-05-25 Herchel Smith Synthesis of 13-alkyl-gon-4-ones
DE3022337A1 (de) * 1980-06-11 1982-01-07 Schering Ag Berlin Und Bergkamen, 1000 Berlin Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen
DE3402329A1 (de) * 1984-01-20 1985-08-01 Schering AG, 1000 Berlin und 4709 Bergkamen 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
FR2739029B1 (fr) * 1995-09-21 1997-11-21 Roussel Uclaf Nouvelle application therapeutique des composes antimineralo-corticoides
DE19651000A1 (de) * 1996-12-01 1998-06-04 Schering Ag Oxyiminopregnancarbolactone

Also Published As

Publication number Publication date
CN101128476B (zh) 2011-02-09
ES2331322T3 (es) 2009-12-29
EP1831240B1 (de) 2009-07-15
JP2008526709A (ja) 2008-07-24
GT200500394A (es) 2006-08-01
BRPI0518533A2 (pt) 2008-11-25
PE20100736A1 (es) 2010-12-03
DE102004063864A1 (de) 2006-07-13
AU2005324055A1 (en) 2006-07-13
PL1831240T3 (pl) 2010-01-29
EA200701239A1 (ru) 2007-12-28
IL184288A0 (en) 2007-10-31
US20090029953A1 (en) 2009-01-29
CR9223A (es) 2007-11-23
DK1831240T3 (da) 2009-11-23
CA2594171C (en) 2012-10-16
JP5043681B2 (ja) 2012-10-10
NO20073257L (no) 2007-08-29
KR20070093443A (ko) 2007-09-18
EP1831240A1 (de) 2007-09-12
PT1831240E (pt) 2009-10-22
AR052657A1 (es) 2007-03-28
NZ556150A (en) 2011-02-25
WO2006072467A1 (de) 2006-07-13
DE502005007723D1 (de) 2009-08-27
UY29320A1 (es) 2006-07-31
EA014325B1 (ru) 2010-10-29
TW200635942A (en) 2006-10-16
PE20060853A1 (es) 2006-09-15
MX2007008074A (es) 2008-03-10
HK1112627A1 (es) 2008-09-12
ZA200706254B (en) 2008-12-31
CY1109498T1 (el) 2014-08-13
CN101128476A (zh) 2008-02-20
SI1831240T1 (sl) 2009-12-31
MY145904A (en) 2012-05-15
EP1831240B8 (de) 2010-02-17
CA2594171A1 (en) 2006-07-13
UA90496C2 (ru) 2010-05-11
RS51128B (sr) 2010-10-31
IL184288A (en) 2011-06-30

Similar Documents

Publication Publication Date Title
PA8658401A1 (es) 18-metil-19-nor-17-pregn-4-en-21, 17-carbolactonas, asi como preparaciones farmaceuticas que las contienen
ECSP055780A (es) Derivados de indol utiles para el tratamiento de enfermedades
BRPI0411528A (pt) uso de isomalte como prebiótico
UY28150A1 (es) Agentes terapeuticos
HN2008001934A (es) 18-metil-19-nor-androst-4-en-17,17-espiroesteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen.
PE20060500A1 (es) Derivados de heteroaril sulfamida benzo-fusionada como anticonvulsivantes
AR023497A1 (es) Ent-esteroides en calidad de estrogenos con efecto selectivo, su empleo para el tratamiento de las enfermedades y los estados motivados por una deficienciade estrogenos en la mujer y en el hombre, y las composiciones farmaceuticas que contienen estos ent-esteroides
CY1106674T1 (el) Αζαδικυκλικοι ετεροκυκλοι σαν ρυθμιστες υποδοχεα κανναβινοειδους
ECSP034542A (es) Nuevos agentes anticolinergicos que se pueden emplear como medicamentos asi como procedimiento para su preparacion
UY28157A1 (es) Miméticos de glucocorticoides métodos para su elaboración composiciones farmacéuticas y sus usos
ECSP055765A (es) Nuevos compuestos de amida con efecto antagónico de la hcm y medicamentos que contienen estos compuestos
CY1110199T1 (el) Φαρμακευτικες συνθεσεις ενος νευροδραστικου στεροειδους και χρησεις αυτων
GT200500368A (es) Analogos de rapamicina y los usos de los mismos en el tratamiento de trastornos neurologicos, proliferativos e inflamatorios
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
UY27918A1 (es) Derivados de benzodioxol
BR0312729A (pt) Novos derivados de indol-3-enxofre
PE20080234A1 (es) Combinacion antiepileptica que comprende derivados de benzoheteroarilsulfamidas
DOP2003000624A (es) Derivados de tropano como moduladores de ccr5
UY26992A1 (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinérgicos y corticoesteroides
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
CO4650117A1 (es) Derivados de bencilsulfuro y proceso para su produccion .
GT199900154A (es) Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas.
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
UY28377A1 (es) Agentes terapeuticos
DK1824479T3 (da) Phenylpiperazin-derivater med en kombination af delvis dopamin-D2-receptoragonisme og serotonin-genoptagelsesinhibering